Updated

The randomized SINGLE-AF trial found that direct oral anticoagulants reduced the risk of serious clinical events by 69% in atrial fibrillation patients with intermediate stroke risk, with the benefit driven mainly by fewer ischemic strokes and no increase in major bleeding. The results support wider use of these blood thinners in a patient population previously considered borderline for anticoagulation therapy, potentially reshaping treatment guidelines for atrial fibrillation.